Cancer treatment is getting meaningfully better, and the proof is in the numbers. About 18.6 million people were living in the United States with a history of cancer as of January 2025, a figure projected to exceed 22 million by 2035. That growing population of survivors reflects decades of compounding progress in how cancers are detected, targeted, and managed. The improvements aren’t uniform across every cancer type, but the overall trajectory is clear.
Immunotherapy Has Changed the Outlook for Several Cancers
The single biggest shift in cancer treatment over the past decade has been immunotherapy, which works by training your own immune system to recognize and attack cancer cells. Before immunotherapy, advanced melanoma was considered nearly untreatable. Now, in stage III melanoma, patients receiving immunotherapy have a three-year overall survival rate of about 75%, compared to roughly 62% for older targeted drug approaches. That gap is even more pronounced in patients under 65, where immunotherapy cut the risk of death by about half.
Immunotherapy has expanded well beyond melanoma. It’s now a standard part of treatment for certain lung cancers, bladder cancers, kidney cancers, and head and neck cancers. The drugs don’t work for everyone, and researchers are still figuring out why some tumors respond dramatically while others don’t. But for the cancers where it does work, it has pushed survival timelines in ways that would have seemed unrealistic 15 years ago.
Targeted Therapy Hits Cancer More Precisely
Older chemotherapy drugs work by killing fast-dividing cells throughout the body, which is why they cause widespread side effects. Targeted therapies take a different approach: they zero in on specific genetic mutations driving a tumor’s growth. In advanced non-small cell lung cancer, patients receiving targeted therapy had a median time before their cancer progressed of about 13 months, compared to 7 months with standard chemotherapy. After one year, 56% of patients on targeted therapy had no disease progression, versus 24% on chemotherapy.
The real power of this approach is specificity. Doctors can now test a tumor’s DNA to find the exact mutation fueling its growth, then match a drug to that mutation. This has turned some advanced cancers from rapid death sentences into conditions that can be managed for years. The tradeoff is that targeted therapies only work when the right mutation is present, and tumors can eventually develop resistance. But the window of disease control they provide is often dramatically longer than what chemotherapy alone could offer.
CAR-T Therapy Is Producing Lasting Remissions
CAR-T cell therapy represents one of the most dramatic advances for blood cancers. The treatment involves removing a patient’s immune cells, genetically engineering them to recognize cancer, and infusing them back. It’s complex and expensive, but for people who have exhausted every other option, the results can be remarkable.
Five-year follow-up data from the LEGEND-2 trial in patients with relapsed or treatment-resistant multiple myeloma showed a five-year overall survival rate of 49%. Among patients who achieved a complete response, that rate climbed to nearly 66%. Perhaps most striking, 16.2% of patients in the trial remained completely relapse-free after five years, with their immune systems fully recovered, regardless of whether they started with high-risk genetic markers. These are patients who had no viable treatment options left. A decade ago, that kind of durable remission in advanced myeloma was essentially unheard of.
AI Is Making Detection Faster and More Accurate
Catching cancer earlier remains one of the most effective ways to improve outcomes, and artificial intelligence is accelerating that process. In breast cancer screening, AI-supported mammography has matched or exceeded radiologist performance while cutting their workload by up to 44%. One large study found AI-assisted screening detected 6.7 cancers per 1,000 screenings compared to 5.7 without AI, a 17.6% improvement, with fewer unnecessary callbacks.
Speed matters too. AI triage in one study reduced the time from screening to additional imaging by 25% and the time to biopsy by 30%, shaving roughly 17 days off the wait. Every cancer flagged as urgent was correctly prioritized. For lung cancer, AI matched radiologist sensitivity in detecting nodules on CT scans and caught 8.4% of nodules that radiologists missed entirely, while cutting the time to read a scan from nearly three minutes to 36 seconds.
These tools aren’t replacing radiologists. They’re functioning as a second set of eyes that never gets fatigued, catching things that might slip through on a busy day and freeing doctors to focus on the cases that need human judgment.
Side Effect Management Has Quietly Improved
For patients still receiving chemotherapy, the experience itself has gotten considerably less brutal. Chemotherapy-induced nausea and vomiting used to be one of the most dreaded aspects of treatment. Newer combination anti-nausea regimens now control both the immediate nausea that hits within hours and the delayed nausea that can linger for days. Palonosetron, for example, is effective against both acute and delayed phases. Low-dose olanzapine, originally developed as a psychiatric medication, has proven surprisingly effective at preventing nausea at a fraction of the cost of newer drugs.
Even simple interventions have gained clinical backing. Ginger supplements have shown real benefit in preventing chemotherapy-related nausea and are far cheaper than pharmaceutical options. These advances in supportive care don’t get the same headlines as immunotherapy breakthroughs, but they directly shape what treatment feels like day to day. Patients who can tolerate their treatment are more likely to complete the full course, which directly affects outcomes.
The Gains Aren’t Equal for Everyone
While the science is advancing, access remains uneven. The immunotherapy data on melanoma, for instance, showed that patients with private insurance saw a more pronounced survival benefit than those without. That pattern repeats across cancer care broadly. Many of the newest treatments carry six-figure price tags. CAR-T therapy can cost hundreds of thousands of dollars for a single course. Targeted therapies require genetic testing that isn’t always covered or available at every hospital.
Geography plays a role too. Patients treated at major cancer centers with access to clinical trials and the latest technology tend to have better outcomes than those at smaller community hospitals. The gap between what’s medically possible and what’s practically available to any given patient remains one of the biggest challenges in oncology. The treatments are getting better. The question increasingly is who gets to benefit from them.